Info

Winston Laboratories, Inc. is a research-based specialty pharmaceutical company that discovers, develops, and commercializes innovative therapeutics for pain. The company's proprietary technologies involve neuroactive compounds which affect the functioning of neurotransmitters that control and mediate pain transmission, most importantly substance P, calcitonin gene-related peptide (CGRP), histamine, and serotonin Based on these technologies, the company is developing potentially important new medications for conditions such as osteoarthritis, cluster headache, migraine headache, chronic daily headache, neuropathic pain syndromes (including painful diabetic neuropathy and postherpetic neuralgia), mucositis, and cancer pain The company's pipeline includes four product candidates in clinical testing and two in preclinical testing. In addition to developing and commercializing new chemical entities, Winston actively discovers and patents new uses and delivery modalities for existing chemical entities that have significant potential for controlling pain. Winston also pursues non-pain-related indications for its proprietary technologies, such as its product in development for depression, and Winston seeks to acquire or in-license pain-related products and technologies that are complementary to its existing portfolio.